• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    NGS based RNA sequencing Market

    ID: MRFR/HC/20519-HCR
    128 Pages
    Rahul Gotadki
    September 2025

    NGS-based RNA-sequencing Market Research Report Information By Product and Service (Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services and Data Analysis, Storage and Management), By Technology (Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing), By Application (Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics), By End-User (Research and Academia, Hosp...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    NGS-based RNA-sequencing Market Research Report — Global Forecast till 2032 Infographic
    Purchase Options
    $ 4,590.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    NGS based RNA sequencing Market Summary

    The Global NGS-based RNA-sequencing Market is projected to grow significantly from 3.2 USD Billion in 2024 to 22.0 USD Billion by 2035.

    Key Market Trends & Highlights

    NGS-based RNA-sequencing Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 19.14% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 22.0 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.2 USD Billion, reflecting the increasing demand for advanced sequencing technologies.
    • Growing adoption of NGS-based RNA-sequencing due to the rising need for personalized medicine is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.2 (USD Billion)
    2035 Market Size 22.0 (USD Billion)
    CAGR (2025-2035) 19.14%

    Major Players

    Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore (the U.S.), Agilent Technologies, Inc. (the U.S.), BGI (China), PerkinElmer Inc. (the U.S.), QIAGEN (Germany), Eurofins Scientific (Luxembourg), Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), Tecan Genomics, Inc. (Switzerland)

    NGS based RNA sequencing Market Trends

      • Increased usage of next-generation sequencing technologies fuels market growth

    The rising implementation of next-generation sequencing technologies is the main driver of the market CAGR for NGS-based RNA-sequencing. Rapid advances in next-generation sequencing techniques, as well as the creation of a human genome database, have enabled companies to provide rapid diagnostic services and the ability to diagnose mutations and disorders in human gene sequences by studying the entire human genome's structure, function, and organization.

    Furthermore, when compared to the traditional Sanger sequencing technique, it significantly reduces the cost of performing sequential studies while also providing improved variant detection power and sensitivity by allowing the sequencing of millions of DNA fragments per run at the same time. The techniques offer great processing speed and throughput, allowing for the generation of a large number of sequences with numerous applications in both research and diagnostics. Researchers are fully researching and developing more prospectuses, which are likely to boost the performance of these procedures as a reliable solution and accelerate global market expansion over the forecast period.

    The NGS-based RNA sequencing market is being driven by the growing field of precision medicine. Precision medicine enables doctors to create personalized treatment regimens and make treatment decisions based on a genetic understanding of the patient's ailment. Precision medicines are becoming increasingly popular for treating serious diseases such as cancer. NGS-based RNA sequencing aids in the identification of the underlying cause of disease and the prescription of precise precision medicine treatments.

    For instance, in September 2021, the Swedish government invested $21.15 million (SEK 220 million) in the Swedish national infrastructure Genomic Medicine Sweden (GMS) to facilitate the continued integration of precision medicine into Swedish healthcare, ensuring that every person has access to more accurate tests and individualized care. Such expenditures are being made because of an increase in demand for precision medications. As demand for precision medicines grows, so will the demand for NGS-based RNA sequencing.

    Moreover, The increasing pharmaceutical industry is likely to drive future growth in the NGS-based RNA-sequencing market. The pharmaceutical industry is the sector in which both government and commercial companies discover, develop, and manufacture pharmaceuticals and medicines. The pharmaceutical sector employs NGS-based RNA-sequencing to thoroughly analyze gene expression, identify prospective drug targets, assess treatment responses, and comprehend disease mechanisms, thereby aiding drug discovery and development through a better understanding of molecular processes.

    For instance, in May 2021, according to reports published by IQVIA Inc., a US-based pharmaceutical company, the projected total expenditure on pharmaceuticals in the US is expected to range between $380 and $400 billion by 2025, up from $359 billion in 2020, reflecting a 0-3% compound annual growth rate. Thus driving the NGS-based RNA-sequencing Market revenue.

    The increasing accessibility of next-generation sequencing technologies is poised to revolutionize RNA analysis, enabling unprecedented insights into gene expression and regulation.

    National Institutes of Health (NIH)

    NGS based RNA sequencing Market Drivers

    Rising Demand for Personalized Medicine

    The Global NGS-based RNA-sequencing Market Industry is experiencing a surge in demand for personalized medicine, driven by advancements in genomics and biotechnology. Personalized medicine tailors treatment strategies based on individual genetic profiles, enhancing therapeutic efficacy. As healthcare systems increasingly adopt precision medicine approaches, RNA-sequencing technologies are pivotal in identifying biomarkers and understanding disease mechanisms. This trend is reflected in the projected market growth, with the Global NGS-based RNA-sequencing Market expected to reach 3.2 USD Billion in 2024 and potentially 22.0 USD Billion by 2035, indicating a robust CAGR of 19.14% from 2025 to 2035.

    Market Segment Insights

    NGS-based RNA-sequencing Product and Service Insights

    The NGS-based RNA-sequencing Market segmentation, based on Product and Service, includes Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services and Data Analysis, Storage and Management. The sequencing platforms and consumables category is expected to dominate the NGS-based RNA-seq Market due to their vital role in the sequencing process. Sequencing platforms and consumables are key components of RNA sequencing because they directly affect the efficiency, accuracy, and throughput of the sequencing protocols. The high cost of these platforms, along with the ongoing need for consumables, ensures that this sector obtains a large portion of market revenue.

    Figure 1: NGS-based RNA-sequencing Market, by Product and Service, 2023 & 2032 (USD Billion)

    NGS-based RNA-sequencing Market, by Product and Service, 2023 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    NGS-based RNA-sequencing Technology Insights

    The NGS-based RNA-sequencing Market segmentation based on Technology includes Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), and Nanopore Sequencing. The Sequencing by Synthesis (SBS) category is predicted to have the biggest revenue share during the forecast period. SBS technology has increased in popularity due to its high accuracy, speed, and cost. It is often used in activities such as alternative splicing analysis, RNA editing analysis, and gene expression profiling.

    Furthermore, advances in chemistry and data analysis techniques are resulting in longer read lengths, fewer error rates, and increased sequencing accuracy, leading to a rise in the use of SBS technology.

    NGS-based RNA-sequencing Application Insights

    The NGS-based RNA-sequencing Market segmentation by Application includes Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling, and Transcriptome Epigenetics. The expression profiling analysis sector is likely to grow the most in the market during the forecast period, owing to its importance in understanding gene function, regulation, and the genetic basis of disease. Expression profile analysis using NGS-based RNA-seq offers unprecedented depth and breadth in assessing the expression levels of thousands of genes at the same time, revealing the molecular signatures of distinct cells and tissues in a range of circumstances.

    NGS-based RNA-sequencing End-User Insights

    The NGS-based RNA-sequencing Market segmentation, based on End-User, includes Research and Academia, Hospitals and Clinics, and Pharmaceutical and Biotechnology Companies. The research and academia sector is expected to develop at the fastest CAGR in the market during the forecast period due to the extensive use of NGS-based RNA sequencing in basic and applied research to get an unprecedented understanding of genomic expressions, variations, and functions. Globally, academia and research organizations invest much in genomic research, employing RNA-seq technologies to examine complex biological challenges, disease mechanisms, and evolutionary studies.

    Regional Insights

    By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America is predicted to have the greatest revenue share during the projection period. The presence of well-established healthcare infrastructure, high healthcare spending, and an increasing prevalence of chronic diseases all contribute to market revenue growth in this region. This region also has a large concentration of major biopharmaceutical companies and sequencing service suppliers. The usage of personalized treatment methods and precision medicine is also fuelling regional market revenue growth.

    Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: NGS-Based RNA-Sequencing Market Share By Region 2023 (USD Billion)

    NGS-Based RNA-Sequencing Market Share By Region 2023 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe NGS-based RNA-sequencing Market accounts for the second-largest market share. The sector is driven by factors such as the proliferation of academic and research institutes, as well as an increase in demand for personalized therapy. Further, the German NGS-based RNA-sequencing Market held the largest market share, and the UK NGS-based RNA-sequencing Market was the fastest-growing market in the European region.

    The Asia-Pacific NGS-based RNA-sequencing Market is expected to grow at the fastest CAGR from 2024 to 2032. The market is being pushed by an increase in genetic research programs, increased healthcare infrastructure expenditure, and growing public awareness of the benefits of personalized treatment. Moreover, China’s NGS-based RNA-sequencing Market held the largest market share, and the Indian NGS-based RNA-sequencing Market was the fastest-growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development in order to expand their product lines, which will help the NGS-based RNA-sequencing Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the NGS-based RNA-sequencing industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global NGS-based RNA-sequencing industry to benefit clients and increase the market sector. In recent years, the NGS-based RNA-sequencing industry has offered some of the most significant advantages to medicine. Major players in the NGS-based RNA-sequencing Market, including Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.) and others, are attempting to increase market demand by investing in research and development operations.

    Thermo Fisher Scientific Inc. is an American company that provides analytical equipment, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services. Thermo Fisher, headquartered in Waltham, Massachusetts, was created in 2006 when Thermo Electron and Fisher Scientific merged. In February 2024, BGI and Berry Genomics announced a collaboration to develop an AI-powered platform for analyzing RNA-seq data. This platform aims to improve the accuracy and efficiency of RNA-seq data analysis, leading to faster and more precise diagnosis and treatment methods.

    QIAGEN N.V. is a German-based international company that develops sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company has around 35 offices throughout 25 countries. QIAGEN N.V., the QIAGEN group's global headquarters, is based in Venlo, Netherlands. The major operational headquarters are in Hilden, Germany. The European, American, Chinese, and Asian-Pacific regional headquarters are located in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. In June 2020, Qiagen launched the QIAcube Connect, a completely automated sample preparation system for NGS and other molecular biology applications.

    The system is intended to deliver high-quality, reproducible outcomes with minimal human participation.

    Key Companies in the NGS based RNA sequencing Market market include

    Industry Developments

    • Q2 2024: Illumina launches NovaSeq X Plus, advancing high-throughput RNA sequencing capabilities Illumina announced the launch of NovaSeq X Plus, a new sequencing platform designed to enhance throughput and accuracy for NGS-based RNA-sequencing applications, targeting clinical and research markets.
    • Q2 2024: Thermo Fisher Scientific unveils Ion Torrent Genexus System for automated RNA sequencing Thermo Fisher Scientific introduced the Ion Torrent Genexus System, an automated NGS platform aimed at streamlining RNA-sequencing workflows for translational research and clinical diagnostics.
    • Q3 2024: Roche partners with Genentech to develop NGS-based RNA-sequencing diagnostics Roche announced a strategic partnership with Genentech to co-develop NGS-based RNA-sequencing diagnostic assays for oncology and rare disease applications.
    • Q3 2024: Bio-Rad Laboratories launches new RNA-seq library preparation kit for NGS platforms Bio-Rad Laboratories released a new RNA-seq library preparation kit optimized for next-generation sequencing, aiming to improve sensitivity and reproducibility in transcriptome analysis.
    • Q4 2024: Agilent Technologies opens new NGS innovation center in Singapore Agilent Technologies inaugurated a new facility in Singapore dedicated to research and development of NGS-based RNA-sequencing technologies, expanding its global footprint in precision genomics.
    • Q4 2024: Pacific Biosciences raises $150M in public offering to expand NGS-based RNA-sequencing portfolio Pacific Biosciences completed a $150 million public offering, with proceeds earmarked for accelerating development of its NGS-based RNA-sequencing products and expanding commercial operations.
    • Q1 2025: Oxford Nanopore Technologies announces partnership with AstraZeneca for RNA-sequencing in drug discovery Oxford Nanopore Technologies entered a partnership with AstraZeneca to deploy NGS-based RNA-sequencing platforms in drug discovery and biomarker identification programs.
    • Q1 2025: Qiagen launches QIAseq FastSelect RNA-seq kit for improved transcriptome profiling Qiagen introduced the QIAseq FastSelect RNA-seq kit, designed to enhance transcriptome profiling efficiency and accuracy for NGS-based RNA-sequencing applications.
    • Q2 2025: BGI Genomics files for $200M IPO to expand NGS-based RNA-sequencing services globally BGI Genomics filed for a $200 million initial public offering, aiming to fund the expansion of its NGS-based RNA-sequencing service offerings in international markets.
    • Q2 2025: Thermo Fisher Scientific acquires Combinati to strengthen NGS-based RNA-sequencing portfolio Thermo Fisher Scientific completed the acquisition of Combinati, a company specializing in digital PCR and RNA-sequencing technologies, to bolster its NGS-based RNA-sequencing product suite.
    • Q3 2025: Illumina appoints new Chief Technology Officer to lead NGS-based RNA-sequencing innovation Illumina announced the appointment of a new Chief Technology Officer, tasked with driving innovation in NGS-based RNA-sequencing platforms and applications.
    • Q3 2025: Agilent Technologies secures contract with major US hospital network for NGS-based RNA-sequencing solutions Agilent Technologies won a contract to supply NGS-based RNA-sequencing solutions to a leading US hospital network, supporting clinical diagnostics and translational research initiatives.

    Future Outlook

    NGS based RNA sequencing Market Future Outlook

    The NGS-based RNA-sequencing market is poised for robust growth, driven by advancements in technology and increasing demand, with a projected 19.14% CAGR from 2024 to 2035.

    New opportunities lie in:

    • Develop integrated platforms combining RNA-sequencing with AI for enhanced data analysis.
    • Expand service offerings to include personalized medicine solutions leveraging RNA insights.
    • Invest in partnerships with biotech firms to accelerate product development and market entry.

    By 2035, the NGS-based RNA-sequencing market is expected to achieve substantial growth, solidifying its position as a critical tool in genomics.

    Market Segmentation

    NGS-based RNA-sequencing End-Use Outlook

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    NGS-based RNA-sequencing Regional Outlook

    • US
    • Canada
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East
    • Africa
    • Latin America

    NGS-based RNA-sequencing Application Outlook

    • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

     NGS-based RNA-sequencing Technology Outlook

    • Sequencing by Synthesis (SBS)
    • Ion Semiconductor Sequencing
    • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    NGS-based RNA-sequencing Product and Service Outlook

    • Sample Preparation Products
    • Sequencing Platforms and Consumables
    • Sequencing Services
    • Data Analysis, Storage and Management

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 USD 2.7 Billion
    Market Size 2024 USD 3.2 Billion
    Market Size 2032 USD 12.4 Billion
    Compound Annual Growth Rate (CAGR) 21.00% (2024-2032)
    Base Year 2023
    Market Forecast Period 2024-2032
    Historical Data 2019-2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product and Service, Technology, Application, End-user and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled  Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.) 149, BGI (China), PerkinElmer Inc. (the U.S.), QIAGEN (Germany), Eurofins Scientific (Luxembourg), Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), Tecan Genomics, Inc. (Switzerland)
    Key Market Opportunities ·         Rise in Genetic Research
    Key Market Dynamics ·         Expanding Applications in Drug Discovery and Development

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    How much is the NGS-based RNA-sequencing Market?

    The NGS-based RNA-sequencing Market size was valued at USD 2.7 Billion in 2023.

    What is the growth rate of the NGS-based RNA-sequencing Market?

    The global market is projected to grow at a CAGR of 21.00% from 2024 to 2032.

    Which region held the largest market share in the NGS-based RNA-sequencing Market?

    North America had the largest share in the global market

    Who are the key players in the NGS-based RNA-sequencing Market?

    The key players in the market are Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.).

    Which product and services sector led the NGS-based RNA-sequencing Market?

    The sequencing platforms and consumables category dominated the market in 2023.

    Which technology had the largest market share in the NGS-based RNA-sequencing Market?

    The Sequencing by Synthesis (SBS) category had the largest share of the global market.

    1. EXECUTIVE SUMMARY
    2. MARKET INTRODUCTION
      1. Definition
      2. Scope of the Study
    3. Research Objective
      1. Assumptions
        1. Limitations
    4. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
    5. Secondary Research
      1. Primary Research
        1. Primary
    6. Interviews and Information Gathering Process
      1. Breakdown of Primary
    7. Respondents
      1. Forecasting Model
      2. Market Size
    8. Estimation
      1. Bottom-Up Approach
        1. Top-Down
    9. Approach
      1. Data Triangulation
      2. Validation
    10. MARKET DYNAMICS
      1. Overview
      2. Drivers
    11. Restraints
      1. Opportunities
    12. MARKET FACTOR ANALYSIS
    13. Value Chain Analysis
      1. Porter’s Five Forces Analysis
    14. Bargaining Power of Suppliers
      1. Bargaining Power of Buyers
    15. Threat of New Entrants
      1. Threat of Substitutes
    16. Intensity of Rivalry
      1. COVID-19 Impact Analysis 
    17. Market Impact Analysis
      1. Regional Impact
    18. Opportunity and Threat Analysis
    19. GLOBAL NGS-BASED RNA-SEQUENCING
    20. MARKET, BY PRODUCT AND SERVICE
      1. Overview
      2. Sample
    21. Preparation Products
      1. Sequencing Platforms and Consumables
    22. Sequencing Services
      1. Data Analysis, Storage and Management
    23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY
      1. Overview
    24. Sequencing by Synthesis (SBS)
      1. Ion Semiconductor Sequencing
    25. Single-molecule Real-time Sequencing (SMRT)
      1. Nanopore Sequencing
    26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION
      1. Overview
    27. Expression Profiling Analysis
      1. Small RNA Sequencing
    28. De Novo Transcriptome Assembly
      1. Variant Calling and Transcriptome
    29. Epigenetics
    30. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY END-USER
    31. Overview 
      1. Research and Academia
      2. Hospitals
    32. and Clinics
      1. Pharmaceutical and Biotechnology Companies
    33. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY REGION
      1. Overview
    34. North America
      1. US
        1. Canada
    35. Europe
      1. Germany
        1. France
    36. UK
      1. Italy
        1. Spain
    37. Rest of Europe
      1. Asia-Pacific
        1. China
    38. India
      1. Japan
        1. South Korea
    39. Australia
      1. Rest of Asia-Pacific
      2. Rest of
    40. the World
      1. Middle East
        1. Africa
    41. Latin America
    42. COMPETITIVE LANDSCAPE
      1. Overview
    43. Competitive Analysis
      1. Market Share Analysis
    44. Major Growth Strategy in the Global NGS-based RNA-sequencing Market,
    45. Competitive Benchmarking
      1. Leading Players in Terms of Number
    46. of Developments in the Global NGS-based RNA-sequencing Market,
    47. Key developments and Growth Strategies
      1. New Product and Service
    48. Launch/Service Deployment
      1. Merger & Acquisitions
    49. Joint Ventures
      1. Major Players Financial Matrix 
    50. Sales & Operating Income, 2023
      1. Major Players R&D Expenditure.
    51. COMPANY PROFILES
      1. Illumina
    52. Company Overview
      1. Financial Overview
    53. Product and Services Offered
      1. Key Developments
    54. SWOT Analysis
      1. Key Strategies
      2. Thermo Fischer
    55. Scientific
      1. Company Overview
        1. Financial
    56. Overview
      1. Product and Services Offered
    57. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    58. Oxford Nanopore
      1. Company Overview
        1. Financial
    59. Overview
      1. Product and Services Offered
    60. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    61. Agilent Technologies, Inc.
      1. Company Overview
    62. Financial Overview
      1. Product and Services Offered
    63. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    64. BGI
      1. Company Overview
        1. Financial Overview
    65. Product and Services Offered
      1. Key Developments
    66. SWOT Analysis
      1. Key Strategies
      2. PerkinElmer
    67. Inc.
      1. Company Overview
        1. Financial Overview
    68. Product and Services Offered
      1. Key Developments
    69. SWOT Analysis
      1. Key Strategies
      2. QIAGEN
    70. Company Overview
      1. Financial Overview
    71. Product and Services Offered
      1. Key Developments
    72. SWOT Analysis
      1. Key Strategies
      2. EUROFINS
    73. SCIENTIFIC
      1. Company Overview
        1. Financial
    74. Overview
      1. Product and Services Offered
    75. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    76. Hoffmann-La Roche Ltd
      1. Company Overview
    77. Financial Overview
      1. Product and Services Offered
    78. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    79. Takara Bio Inc.
      1. Company Overview
        1. Financial
    80. Overview
      1. Product and Services Offered
    81. Key Developments
      1. SWOT Analysis
        1. Key
    82. Strategies
      1. Tecan Genomics, Inc
        1. Company
    83. Overview
      1. Financial Overview
        1. Product
    84. and Services Offered
      1. Key Developments
    85. SWOT Analysis
      1. Key Strategies
    86. APPENDIX
    87. References
      1. Related Reports
    88. LIST
    89. OF TABLES
    90. & FORECAST, 2019-2032 (USD BILLION)
    91. MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD BILLION)
    92. NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)
    93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    94. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    95. NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    96. (USD BILLION) 
    97. MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION) 
    98. AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION) 
    99. NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    100. US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD BILLION)
    101. US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION)
    102. US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    103. US: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    104. CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    105. BILLION)
    106. 2032 (USD BILLION)
    107. MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    108. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    109. EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    110. BILLION)
    111. 2032 (USD BILLION)
    112. BY APPLICATION, 2019-2032 (USD BILLION)
    113. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    114. GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    115. BILLION)
    116. 2032 (USD BILLION)
    117. MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    118. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    119. FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    120. BILLION)
    121. 2032 (USD BILLION)
    122. MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    123. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    124. ITALY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    125. BILLION)
    126. 2032 (USD BILLION)
    127. BY APPLICATION, 2019-2032 (USD BILLION)
    128. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    129. SPAIN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    130. BILLION)
    131. 2032 (USD BILLION)
    132. BY APPLICATION, 2019-2032 (USD BILLION)
    133. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    134. UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD BILLION)
    135. UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION) 
    136. UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    137. UK: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    138. REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    139. (USD BILLION)
    140. BY TECHNOLOGY, 2019-2032 (USD BILLION)
    141. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    142. REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD
    143. BILLION)
    144. PRODUCT AND SERVICE, 2019-2032 (USD BILLION) 
    145. NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION) 
    146. ASIA-PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD
    147. BILLION) 
    148. BY END-USER, 2019-2032 (USD BILLION)
    149. MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD BILLION)
    150. NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION) 
    151. JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION) 
    152. JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    153. CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    154. BILLION)
    155. 2032 (USD BILLION) 
    156. MARKET, BY APPLICATION, 2019-2032 (USD BILLION) 
    157. NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    158. INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    159. BILLION) 
    160. TECHNOLOGY, 2019-2032 (USD BILLION) 
    161. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION) 
    162. INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    163. AUSTRALIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    164. (USD BILLION)
    165. BY TECHNOLOGY, 2019-2032 (USD BILLION)
    166. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    167. AUSTRALIA: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    168. SOUTH KOREA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    169. (USD BILLION)
    170. BY TECHNOLOGY, 2019-2032 (USD BILLION)
    171. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    172. SOUTH KOREA: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    173. REST OF ASIA-PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE,
    174. 2032 (USD BILLION) 
    175. RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032 (USD BILLION) 
    176. REST OF ASIA-PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032
    177. (USD BILLION) 
    178. MARKET, BY END-USER, 2019-2032 (USD BILLION)
    179. WORLD: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD BILLION)
    180. REST OF THE WORLD: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2019-2032
    181. (USD BILLION)
    182. MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    183. WORLD: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    184. MIDDLE EAST: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    185. (USD BILLION)
    186. BY TECHNOLOGY, 2019-2032 (USD BILLION)
    187. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    188. MIDDLE EAST: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    189. AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032 (USD
    190. BILLION)
    191. 2032 (USD BILLION)
    192. MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    193. RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    194. LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2019-2032
    195. (USD BILLION)
    196. BY TECHNOLOGY, 2019-2032 (USD BILLION)
    197. RNA-SEQUENCING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
    198. LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END-USER, 2019-2032 (USD BILLION)
    199. LIST
    200. OF FIGURES
    201. STRUCTURE FOR THE GLOBAL NGS-BASED RNA-SEQUENCING MARKET
    202. MARKET DYNAMICS FOR THE GLOBAL NGS-BASED RNA-SEQUENCING MARKET
    203. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY PRODUCT AND SERVICE, 2023
    204. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY TECHNOLOGY, 2023 
    205. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY APPLICATION, 2023 
    206. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY END-USER, 2023 
    207. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY REGION, 2023
    208. NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY REGION, 2023 
    209. EUROPE: NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY REGION, 2023
    210. ASIA-PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY REGION, 2023
    211. REST OF THE WORLD: NGS-BASED RNA-SEQUENCING MARKET, SHARE (%), BY REGION, 2023 
    212. GLOBAL NGS-BASED RNA-SEQUENCING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
    213. ILLUMINA: FINANCIAL OVERVIEW SNAPSHOT
    214. ANALYSIS 
    215. SNAPSHOT
    216. OXFORD NANOPORE: FINANCIAL OVERVIEW SNAPSHOT
    217. SWOT ANALYSIS
    218. SNAPSHOT
    219. BGI.: FINANCIAL OVERVIEW SNAPSHOT
    220. PERKINELMER INC.: FINANCIAL OVERVIEW SNAPSHOT
    221. INC.: SWOT ANALYSIS 
    222. QIAGEN: SWOT ANALYSIS
    223. OVERVIEW SNAPSHOT
    224. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
    225. ROCHE LTD: SWOT ANALYSIS 
    226. OVERVIEW SNAPSHOT
    227. TECAN GENOMICS, INC: FINANCIAL OVERVIEW SNAPSHOT
    228. GENOMICS, INC: SWOT ANALYSIS 

    NGS-based RNA-sequencing Market Segmentation

    NGS-based RNA-sequencing Product & Services Outlook (USD Billion, 2019-2032)

    • Sample Preparation Products
    • Sequencing Platforms and Consumables
    • Sequencing Services
    • Data Analysis, Storage and Management

    NGS-based RNA-sequencing Technology Outlook (USD Billion, 2019-2032)

    • Sequencing By Synthesis (SBS)
    • Ion Semiconductor Sequencing
    • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    NGS-based RNA-sequencing Application Outlook (USD Billion, 2019-2032)

    • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    NGS-based RNA-sequencing End-user Outlook (USD Billion, 2019-2032)

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    NGS-based RNA-sequencing Regional Outlook (USD Billion, 2019-2032)

    • North America Outlook (USD Billion, 2019-2032)

    • North America NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • North America NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • North America NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • North America NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • US Outlook (USD Billion, 2019-2032)

    • US NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • US NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • US NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • US NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • CANADA Outlook (USD Billion, 2019-2032)

    • CANADA NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • CANADA NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • CANADA NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • CANADA NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Europe Outlook (USD Billion, 2019-2032)

    • Europe NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Europe NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Europe NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Europe NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Germany Outlook (USD Billion, 2019-2032)

    • Germany NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Germany NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Germany NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Germany NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • France Outlook (USD Billion, 2019-2032)

    • France NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • France NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • France NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • France NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • UK Outlook (USD Billion, 2019-2032)

    • UK NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • UK NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • UK NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • UK NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • ITALY Outlook (USD Billion, 2019-2032)

    • ITALY NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • ITALY NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • ITALY NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • ITALY NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • SPAIN Outlook (USD Billion, 2019-2032)

    • Spain NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • SpainNGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • SpainNGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Spain NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Rest Of Europe Outlook (USD Billion, 2019-2032)

    • Rest Of Europe NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • REST OF EUROPE NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • REST OF EUROPE NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Rest Of Europe NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Asia-Pacific Outlook (USD Billion, 2019-2032)

    • Asia-Pacific NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Asia-Pacific NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Asia-Pacific NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Asia-Pacific NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • China Outlook (USD Billion, 2019-2032)

    • China NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • China NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • China NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • China NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Japan Outlook (USD Billion, 2019-2032)

    • Japan NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Japan NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Japan NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Japan NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • India Outlook (USD Billion, 2019-2032)

    • India NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • India NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • India NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • India NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Australia Outlook (USD Billion, 2019-2032)

    • Australia NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Australia NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Australia NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Australia NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)

    • Rest of Asia-Pacific NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Rest of Asia-Pacific NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Rest of Asia-Pacific NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Rest of Asia-Pacific NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Rest of the World Outlook (USD Billion, 2019-2032)

    • Rest of the World NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Rest of the World NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Rest of the World NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Rest of the World NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    Middle East Outlook (USD Billion, 2019-2032)

    • Middle East NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Middle East NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Middle East NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Middle East NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Africa Outlook (USD Billion, 2019-2032)

    • Africa NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Africa NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencing

    • Africa NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Africa NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies

    • Latin America Outlook (USD Billion, 2019-2032)

    • Latin America NGS-based RNA-sequencing By Product & Services

      • Sample Preparation Products
      • Sequencing Platforms and Consumables
      • Sequencing Services
      • Data Analysis, Storage and Management

    • Latin America NGS-based RNA-sequencing By Technology

      • Sequencing By Synthesis (SBS)
      • Ion Semiconductor Sequencing
      • Single-molecule Real-time Sequencing (SMRT)
    • Nanopore Sequencings

    • Latin America NGS-based RNA-sequencing By Application

      • Expression Profiling Analysis
    • Small RNA Sequencing
    • De Novo Transcriptome Assembly
    • Variant Calling and Transcriptome Epigenetics

    • Latin NGS-based RNA-sequencing By End-user

    • Research and Academia
    • Hospitals and Clinics
    • Pharmaceutical and Biotechnology Companies
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027